9,004 Shares in Abbott Laboratories $ABT Acquired by IMS Capital Management

IMS Capital Management acquired a new stake in Abbott Laboratories (NYSE:ABT) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 9,004 shares of the healthcare product maker’s stock, valued at approximately $1,225,000.

Other institutional investors have also recently bought and sold shares of the company. Hughes Financial Services LLC bought a new position in shares of Abbott Laboratories in the 1st quarter worth $27,000. Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth about $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories in the 1st quarter valued at approximately $30,000. JCIC Asset Management Inc. acquired a new position in Abbott Laboratories during the first quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC acquired a new stake in Abbott Laboratories in the first quarter worth $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ABT. BTIG Research dropped their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Royal Bank Of Canada lifted their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Mizuho increased their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Finally, Raymond James Financial reduced their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.22.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Shares of ABT opened at $135.82 on Wednesday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a 50 day moving average of $130.65 and a 200-day moving average of $131.15. The stock has a market capitalization of $236.39 billion, a P/E ratio of 17.02, a P/E/G ratio of 2.59 and a beta of 0.69. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the business earned $1.14 EPS. The company’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.